Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Disease – Global Clinical Trials Review, H1 2020

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report

Published: May 30, 2020 Report Code: GDHC6245CTIDB-ST

Select Item

GlobalData's clinical trial report, “Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Global Clinical Trials Review, H1, 2020" provides an overview of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

– Assists in formulating key business strategies with regards to investment

– Helps in identifying prominent locations for conducting clinical trials which saves time and cost

– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

– Supports understanding of trials count and enrollment trends by country in global therapeutics market

– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

– Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

UroGen Pharma Ltd
Merck & Co Inc
Spectrum Pharmaceuticals Inc
Anchiano Therapeutics Ltd
Asieris Pharmaceuticals Co Ltd
AstraZeneca Plc
Bristol-Myers Squibb Co
Liminal BioSciences Inc
CG Oncology Inc
Altor Bioscience LLC

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 7

GlobalData Clinical Trials Report Coverage 8

Clinical Trials by Region 9

Clinical Trials and Average Enrollment by Country 10

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 13

Top Five Countries Contributing to Clinical Trials in Europe 14

Top Countries Contributing to Clinical Trials in North America 15

Top Countries Contributing to Clinical Trials in Middle East and Africa 16

Top Countries Contributing to Clinical Trials in Central and South America 17

Clinical Trials by G7 Countries: Proportion of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) to Oncology Clinical Trials 18

Clinical Trials by Phase in G7 Countries 20

Clinical Trials in G7 Countries by Trial Status 22

Clinical Trials by E7 Countries: Proportion of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) to Oncology Clinical Trials 24

Clinical Trials by Phase in E7 Countries 26

Clinical Trials in E7 Countries by Trial Status 27

Clinical Trials by Phase 29

In Progress Trials by Phase 30

Clinical Trials by Trial Status 31

Clinical Trials by End Point Status 33

Subjects Recruited Over a Period of Time 34

Clinical Trials by Sponsor Type 35

Prominent Sponsors 36

Top Companies Participating in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials 38

Prominent Drugs 40

Latest Clinical Trials News on Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) 42

Feb 25, 2020: Theralase advances its pivotal phase II non-muscle invasive bladder cancer study with a new clinical study site in Nova Scotia 42

Clinical Trial Profile Snapshots 43

Appendix 181

Abbreviations 181

Definitions 181

Research Methodology 182

Secondary Research 182

About GlobalData 183

Contact Us 183

Disclaimer 183

Source 184

Table

List of Tables

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Region, 2020* 8

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020* 10

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020* 11

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2020* 12

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries, 2020* 13

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, North America, Top Countries, 2020* 14

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2020* 15

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Central and South America, Top Countries, 2020* 16

Proportion of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) to Oncology Clinical Trials, G7 Countries (%), 2020* 18

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020* 20

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020* 22

Proportion of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) to Oncology Clinical Trials, E7 Countries (%), 2020* 24

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020* 25

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020* 27

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Phase, 2020* 28

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase 2020* 29

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2020* 31

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2020* 32

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019 33

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2020* 34

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2020* 36

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020* 38

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020* 40

Figures

List of Figures

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Region (%), 2020* 8

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020* 9

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020* 11

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020* 12

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020* 13

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, North America, Top Countries (%), 2020* 14

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2020* 15

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2020* 16

Proportion of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) to Oncology Clinical Trials, G7 Countries (%), 2020* 17

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020* 19

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020* 21

Proportion of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) to Oncology Clinical Trials, E7 Countries (%), 2020* 23

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020* 25

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020* 26

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Phase (%), 2020* 28

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase, 2020* 29

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2020* 30

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2020* 32

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019 33

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020* 34

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2020* 35

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020* 37

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020* 39

GlobalData Methodology 181

 

Frequently asked questions

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Disease – Global Clinical Trials Review, H1 2020 standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Generic Drugs - Physician Perspective - Thematic Intelligence
$1,495 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Disease – Global Clinical Trials Review, H1 2020 in real time.

  • Access a live Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Disease – Global Clinical Trials Review, H1 2020 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more